Biliary and pancreatic complications of molecular targeted therapies in cancer imaging

Abstract

The purpose of this review is to familiarize radiologists with the different imaging manifestations of biliary and pancreatic toxicity of molecular targeted therapies. The advent of molecular targeted therapies for cancer treatment has prompted radiologists to be familiar with these new molecules, their patterns of response, and their class-specific toxicities. While liver and bowel toxicities have been extensively reported in literature, less is known about the pathogenesis and imaging of toxicity involving the pancreatobiliary system. Biliary and pancreatic toxicity of molecular targeted therapies present with variable manifestations and varying degrees of severity, from asymptomatic liver function tests elevation to acute pancreatitis or cholecystitis. Management of these conditions depends on the clinical scenario and the severity of the findings. In this article, we will (1) present the various classes of molecular targeted therapies most commonly associated with biliary and pancreatic toxicity; (2) illustrate imaging findings of drug-associated biliary and pancreatic injuries and their possible differential diagnosis; and (3) provide a guide for management of these conditions.

Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe

“…Pancreatic atrophy is associated with long-term use of sunitinib and sorafenib [ 10 , 57 , 58 ]. Also ICIs can induce irreversible pancreatic atrophy that can lead to exocrine pancreatic insufficiency [ 59 ].…”